News
Giving pregnant women cash transfers cuts infant mortality in half, study finds
Giving pregnant women unconditional cash transfers of US$1,000 in rural Kenya cut infant mortality by 49 per cent, new research has found.
The one-time payments, about three-quarters of annual household income, also reduced deaths in children under five by 45 per cent when the money arrived around the time of birth.
The findings suggest that direct financial support to expectant mothers can improve survival rates for babies and young children in low-resource areas.
The research was carried out by associate professor Dennis Egger from the University of Oxford’s Department of Economics and Centre for the Study of African Economies, working with colleagues at the University of California, Berkeley.
It evaluated a large-scale cash transfer programme run by non-government organisation GiveDirectly.
The team analysed regional census data on more than 100,000 children across 10,500 low-income households in 650 villages.
The study used a randomised controlled trial, a research method widely seen as the most reliable way to test cause and effect.
The reduction in deaths was linked to fewer cases of largely preventable conditions that appropriate obstetric care – medical support during pregnancy and childbirth – could have treated.
The impact was strongest in the poorest households.
Several factors appeared to play a role, including higher rates of hospital births, better nutrition, and more time for mothers to rest during and after pregnancy.
Access to quality healthcare was also important in achieving these improvements.
Associate professor Egger said: “Although the unconditional cash transfers were not primarily designed for this, our research shows that they may be a cost-effective way to reduce infant and child deaths.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now








